五星体育直播 Announces Appointment of Raymond De Vr茅, PhD, to Board of Directors
REDWOOD CITY, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 五星体育直播 (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Raymond De Vr茅, PhD, to the Company鈥檚 Board of Directors.
鈥淲e are thrilled to have Raymond join the 五星体育直播 Board of Directors. He will be an invaluable resource to 五星体育直播,鈥� said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at 五星体育直播. 鈥淩aymond brings a deep understanding of the commercial and regulatory landscape as well as direct experience in oligonucleotide manufacturing.鈥�
鈥溛逍翘逵辈� and its ECO Synthesis platform represent the next generation of innovation for oligonucleotide development and manufacturing. I鈥檓 excited to partner with the rest of the Board and the executive team as we build a strong and sustainable business on the foundation of this unique technology platform,鈥� said Dr. De Vr茅.
Dr. De Vr茅 brings over 20 years of executive-level experience to 五星体育直播. He currently serves as Managing Director at RADV Advisory, an independent strategic and operational advisory company focused on investments in the global healthcare and contract development and manufacturing organization (CDMO) space. Prior to founding RADV Advisory, he was the Chief Executive Officer of PolyPeptide Group, a CDMO focused on peptide- and oligonucleotide-based therapies for pharmaceutical and biotech companies globally. Prior to PolyPeptide, Dr. De Vr茅 held multiple senior leadership roles at Dr. Reddy鈥檚 Laboratories, including Senior Vice President, Head of Biologics, and served as a member of the Management Council. Earlier in his career, he was a Partner at McKinsey & Company, working mostly in the pharmaceutical and biotech practice. Dr. De Vr茅 holds a PhD in Applied Physics from Stanford University and a master鈥檚 degree in engineering from Universit茅 Libre de Bruxelles.
About 五星体育直播
五星体育直播 is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver庐聽technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. 五星体育直播 enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis鈩� manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. 五星体育直播鈥� unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit聽.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as 鈥渁im,鈥� 鈥渁nticipate,鈥� 鈥渁ssume,鈥� 鈥渂elieve,鈥� 鈥渃ontemplate,鈥� 鈥渃ontinue,鈥� 鈥渃ould,鈥� 鈥渄esign,鈥� 鈥渄ue,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥済oal,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥渙bjective,鈥� 鈥減lan,鈥� 鈥減ositioned,鈥� 鈥減otential,鈥� 鈥減redict,鈥� 鈥渟eek,鈥� 鈥渟hould,鈥� 鈥渟uggest,鈥� 鈥渢arget,鈥� 鈥渙n track,鈥� 鈥渨ill,鈥� 鈥渨ould鈥� and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. To the extent that statements contained in this press release are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management, including but not limited to statements regarding the potential of the ECO Synthesis鈩� platform, and it providing an opportunity for 五星体育直播 to efficiently capture meaningful market share; expectations regarding 五星体育直播 meeting its technical and commercial milestones regarding the ECO Synthesis鈩� platform; and expectations regarding the potential of and future demand for RNAi therapeutics, and whether 五星体育直播 will be able to capitalize on such demand. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond 五星体育直播鈥� control and that could materially affect actual results. Factors that could materially affect actual results include, among others: 五星体育直播鈥� dependence on its licensees and collaborators; if any of its collaborators terminate their development programs under their respective license agreements with 五星体育直播; 五星体育直播 may need additional capital in the future in order to expand its business; if 五星体育直播 is unable to successfully develop and commercialize new technology such as its ECO Synthesis鈩� platform and its dsRNA ligase; 五星体育直播 dependence on a limited number of products and customers, and potential adverse effects to 五星体育直播鈥� business if its customers鈥� products are not received well in the markets; if competitors and potential competitors who have greater resources and experience than 五星体育直播 develop products and technologies that make 五星体育直播鈥� products and technologies obsolete; if 五星体育直播 is unable to accurately forecast financial and operational performance; and market and economic conditions may negatively impact 五星体育直播 business, financial condition and share price. Additional information about factors that could materially affect actual results can be found in 五星体育直播鈥� Annual Report on Form 10-K filed with the Securities and Exchange Commission (鈥淪EC鈥�) on February 28, 2024 and in 五星体育直播鈥� Quarterly Report on Form 10-Q filed with the SEC on October 31, 2024, including under the caption 鈥淩isk Factors,鈥� and in 五星体育直播鈥� other periodic reports filed with the SEC. 五星体育直播 expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
Media Contact
Lauren Musto
(650) 421-8205
Source: 五星体育直播
Released November 12, 2024